The Alzheimer’s genetic hit list just got a little longer. A cadre of scientists, led by Emil Uffelmann, Douglas Wightman, and Danielle Posthuma at VU Amsterdam in the Netherlands, and Ole Andreassen ...
In very rare cases, people who underwent brain surgery as children have developed cerebral amyloid angiopathy in middle age, hinting that those procedures had transmitted seeds of misfolded Aβ. Though ...
For the dopaminergic neurons that are especially vulnerable in Parkinson’s disease, a glut of cholesterol may be a death sentence. That’s according to scientists led by Ming Lu and Lei Cao at Nanjing ...
Calling all lipid enthusiasts! Scientists have put together a three-dimensional map of where these molecules reside throughout the entire mouse brain. Using high-tech mass-spec imaging, researchers ...
How do some people resist the effects of Alzheimer’s pathology better than others? In the October 27 Neuron, scientists led by Dan Liu and Ling-Qiang Zhu at Huazhong University of Science and ...
Research animals raised in cool environments live longer, but why is this so? In the October 21 Nature, scientists led by Hyun Ju Lee and David Vilchez at the University of Cologne, Germany, proposed ...
Genes: Plcg2, APP, PSEN1 Modification: Plcg2: Knock-In; APP: Transgenic; PSEN1: Transgenic Disease Relevance: Alzheimer's Disease Strain Name: N/A Genetic Background ...
To mark the 20th anniversary of Alzforum's launch in 1996, we have compiled a timeline reflecting the evolution of Alzheimer’s disease research, starting from Alois Alzheimer's public presentation of ...
The competition supports research projects that develop and implement Artificial Intelligence (AI) and technology approaches to improve the health and well-being of older adults, including people ...
Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...
Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results